Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Photo: Getty Images Eli Lilly & Co. said Thursday it has agreed to acquire Sigilon Therapeutics Inc. in a deal worth up to $309.6 million, sending Sigilon’s stock up 550%.